Kawasaki Disease with Persistent Fever

Overview

Kawasaki disease (KD) is an acute, self‑limited vasculitis that primarily targets medium‑size arteries, especially the coronary arteries. When the fever lasts ≥ 5 days despite standard anti‑inflam­matory therapy, clinicians describe it as “Kawasaki disease with persistent fever.” Persistent fever signals a higher risk of coronary aneurysm formation and often requires more aggressive treatment.

Key points:

• Typical age: 6 months to 5 years; 80 % of cases occur before age 3.
• Sex: Boys are affected about 1.5‑2 times more often than girls.
• Geography: Highest incidence in East Asia (Japan ≈ 264 per 100 000 children < 5 y; Korea ≈ 109/100 000). In the United States, incidence is ≈ 20‑25 per 100 000 children < 5 y.
• Seasonality: Peaks in winter‑spring, suggesting an infectious trigger.

Symptoms

Kawasaki disease is diagnosed clinically. The classic “complete” presentation requires fever ≥ 5 days plus 4 of the 5 principal features. In “incomplete” or “persistent‑fever” cases, clinicians may rely on laboratory and imaging findings.

Principal clinical features

• Fever: High‑grade (≥ 39 °C/102.2 °F), daily, lasting ≥ 5 days; often unresponsive to antipyretics.
• Conjunctival injection: Bilateral, non‑exudative redness of the eyes without crusting.
• Oral changes: Strawberry tongue, cracked or fissured lips, erythema of the oral mucosa.
• Peripheral extremity changes: Redness of palms/soles, edema of hands/feet, later desquamation (peeling) of fingers and toes.
• Polymorphous rash: Usually diffuse erythema, can be scarlatiniform, urticarial, or vesicular.
• Cervical lymphadenopathy: Unilateral, firm, > 1.5 cm, usually painless.

Additional findings that raise suspicion

• Irritability (common in infants).
• Arthralgia or transient arthritis.
• Gastrointestinal symptoms – vomiting, abdominal pain, diarrhea.
• Respiratory symptoms – cough, mild rhinorrhea.
• Hepatomegaly or mild transaminitis.

Causes and Risk Factors

The exact cause of KD remains unknown, but prevailing theories involve an abnormal immune response to an environmental trigger (likely infectious) in genetically susceptible children.

Potential triggers

• Respiratory or gastrointestinal viral agents (e.g., adenovirus, rhinovirus, SARS‑CoV‑2) have been detected in some outbreaks.
• Bacterial superantigens – hypothesized based on immune‑profile similarities to toxic‑shock syndrome.

Genetic predisposition

• Polymorphisms in I​B​K​B​α, TCF​4, and HLA‑B51 are linked to increased susceptibility.
• Higher incidence among Asian ancestry (Japanese, Korean, Taiwanese) even after migration.

Risk factors for persistent fever and worse outcomes

• Male sex, age < 1 year, or age > 5 years.
• Late presentation (≥ 10 days after fever onset).
• Elevated inflammatory markers (CRP ≥ 10 mg/dL, ESR ≥ 80 mm/hr).
• Low serum albumin (< 3 g/dL) or neutrophil-predominant leukocytosis.
• Resistance to first‑line intravenous immunoglobulin (IVIG).

Diagnosis

There is no single confirmatory test. Diagnosis relies on a combination of clinical criteria, laboratory evidence of systemic inflammation, and cardiac imaging.

Clinical criteria (American Heart Association, 2017)

• Fever ≥ 5 days + 4 of 5 principal features → “complete” KD.
• Fever ≥ 5 days + 2–3 principal features + compatible laboratory or echocardiographic findings → “incomplete” KD.

Laboratory studies

Typical finding	Interpretation
Elevated CRP & ESR	Markers of acute inflammation.
Leukocytosis with neutrophilia	Supports active vasculitis.
Thrombocytosis (platelets ≥ 450 × 10⁹/L after day 7)	Characteristic of sub‑acute phase.
Low serum albumin	Associated with higher risk of coronary aneurysm.
Elevated liver enzymes, sterile pyuria	Non‑specific but common.

Cardiac imaging

• Echocardiography: First‑line to detect coronary artery dilation or aneurysms, valvular regurgitation, and pericardial effusion.
• Cardiac MRI or CT angiography: Used when echo windows are poor or to delineate aneurysm anatomy.

Other ancillary tests

• Urinalysis – sterile pyuria.
• Chest X‑ray – may show mild cardiomegaly or pulmonary congestion.
• Serologic testing for common viruses/bacteria – mainly to exclude mimickers.

Treatment Options

Prompt treatment within the first 10 days dramatically reduces coronary complications—from ~25 % to < 5 %.

First‑line therapy

• Intravenous Immunoglobulin (IVIG): 2 g/kg as a single infusion over 10‑12 hours.
• Aspirin: High‑dose (80‑100 mg/kg/day divided q6h) until the patient is afebrile for 48 h, then low‑dose (3‑5 mg/kg/day) for antiplatelet effect (typically 6‑8 weeks or longer if coronary changes persist).

Management of persistent fever (IVIG‑resistant)

≈ 10‑20 % of children do not become afebrile after the first IVIG dose.

• Second dose of IVIG: Repeat 2 g/kg.
• Corticosteroids: Methylprednisolone 30 mg/kg/day IV for 1‑3 days, then oral taper (e.g., prednisone 2 mg/kg/day) – especially in high‑risk patients per the “Kobayashi score.”
• Infliximab (anti‑TNFα): 5‑10 mg/kg IV single dose; useful when IVIG + steroids fail.
• Cyclosporine: Considered in refractory cases (dose 5 mg/kg/day divided BID, target trough 100‑200 ng/mL).
• Plasma exchange: Rare, reserved for life‑threatening coronary involvement.

Supportive care

• Hydration and antipyretics (acetaminophen) for comfort.
• Monitoring of electrolytes, renal function, and platelet counts.
• Daily cardiac exams and repeat echocardiograms (at diagnosis, 1–2 weeks, 6‑8 weeks, and then as indicated).

Lifestyle & activity recommendations during acute phase

• Limit vigorous activity until coronary status is confirmed normal.
• Maintain a balanced diet; avoid dehydration.
• Continue low‑dose aspirin only under physician supervision.

Living with Kawasaki disease with persistent fever

Even after the acute illness resolves, families may face anxiety about heart health and future infections.

Home monitoring

• Record temperature three times daily; note any rise above 38 °C (100.4 °F).
• Observe skin for new rashes or peeling.
• Watch for swelling or pain in joints.
• Maintain a symptom diary to share at follow‑up visits.

Follow‑up schedule

• Cardiology visit within 1 week of discharge.
• Echocardiogram at 2 weeks, 6‑8 weeks, 6 months, and yearly until coronary arteries are confirmed normal.
• Immunizations can continue as scheduled; no live vaccines are contraindicated after IVIG.

School and childcare

• Inform teachers and caregivers about the diagnosis and need for fever monitoring.
• Provide a written plan for emergency medication (e.g., aspirin) if prescribed.
• Encourage hand hygiene to reduce secondary infections.

Emotional support

• Connect with support groups (e.g., The Kawasaki Disease Foundation).
• Consider counseling for children who experience prolonged hospital stays.

Prevention

Because the trigger is unidentified, primary prevention is limited. However, several measures can reduce the risk of severe disease or complications:

• Prompt medical evaluation for any child with fever > 5 days plus rash, red eyes, or swollen lymph node.
• Maintain routine vaccinations – they do not increase KD risk and protect against infections that could act as triggers.
• Practice good infection control (hand washing, avoiding exposure to sick contacts) especially during winter‑spring peaks.
• Family history awareness: siblings of a child with KD have a modestly increased risk; discuss this with pediatrician.

Complications

When untreated or inadequately treated, KD can lead to serious, sometimes life‑threatening outcomes.

• Coronary artery aneurysm (CAA): Occurs in 15‑25 % of untreated cases; can progress to thrombosis, myocardial infarction, or sudden cardiac death.
• Myocarditis & pericarditis: May cause heart failure or arrhythmias.
• Valvular regurgitation: Usually mild, resolves over months.
• Peripheral neuropathy: Rare, manifests as facial palsy.
• Gastrointestinal bleeding: From vasculitis of mesenteric vessels.
• Long‑term sequelae: Persistent coronary artery dilation requiring lifelong cardiology care, antiplatelet therapy, or even coronary artery bypass grafting in severe aneurysms.

When to Seek Emergency Care

---

Sources: American Heart Association. “Kawasaki Disease.” 2023; Mayo Clinic. “Kawasaki disease.” 2024; CDC. “Kawasaki Disease (Mucocutaneous Lymph Node Syndrome).” 2022; WHO. “Kawasaki disease” fact sheet 2023; Cleveland Clinic. “Kawasaki disease: Symptoms, causes, treatment.” 2024; Kobayashi et al., J Pediatr 2020; Newburger JW et al., N Engl J Med 2016.